<DOC>
	<DOCNO>NCT00373659</DOCNO>
	<brief_summary>This study design evaluate variable dose regimen intravitreal ranibizumab treatment patient neovascular age-related macular degeneration ( AMD ) Prospective OCT Imaging Patients Neovascular AMD Treated Intra-Ocular Ranibizumab ( PrONTO ) study .</brief_summary>
	<brief_title>An OCT-Guided Variable Dosing Regimen With Ranibizumab Treatment Neovascular AMD</brief_title>
	<detailed_description>In 2-year open-label , prospective , single-center , uncontrolled , investigator sponsor clinical study , neovascular AMD patient subfoveal CNV ( N=40 ) central retinal thickness least 300 µm measure optical coherence tomography ( OCT ) enrol receive 3 consecutive monthly intravitreal injection ranibizumab ( 0.5 mg ) . Thereafter , retreatment ranibizumab perform one follow change observe visit : loss 5 letter conjunction fluid macula detect OCT , increase OCT central retinal thickness least 100 μm , new onset classic CNV , new macular hemorrhage , persistent macular fluid follow injection ranibizumab prior study visit .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Age 50 year older Active primary recurrent macular neovascularization secondary agerelated macular degeneration ( AMD ) involve central fovea study eye evidence disease progression OCT central retinal thickness ≥ 300 micron Best correct visual acuity , use ETDRS chart , 20/40 20/400 ( Snellen equivalent ) study eye More 3 prior treatment verteporfin photodynamic therapy Previous participation clinical trial ( either eye ) involve antiangiogenic drug ( pegaptanib , ranibizumab , anecortave acetate , protein kinase C inhibitor ) Previous subfoveal focal laser photocoagulation study eye Laser photocoagulation ( juxtafoveal extrafoveal ) study eye within 1 month precede day 0 Subfoveal fibrosis atrophy study eye History vitrectomy surgery study eye Aphakia absence posterior capsule study eye History idiopathic autoimmuneassociated uveitis either eye</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Neovascularization</keyword>
	<keyword>Age-related macular degeneration</keyword>
	<keyword>Ranibizumab ( Lucentis )</keyword>
	<keyword>Optical coherence tomography</keyword>
	<keyword>Intravitreal injection</keyword>
</DOC>